Related Experiment Video

Updated: Mar 24, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

MDA-9/Syntenin small molecule inhibitor IVMT-Rx-4 blocks prostate cancer bone metastasis

Santanu Maji1, Amit Kumar1, Padmanabhan Mannangatti1

  • 1VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States; Department of Cellular, Molecular and Genetic Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.

Pharmacological Research
|March 22, 2026
PubMed

Insights

A new drug, IVMT-Rx-4, inhibits prostate cancer (PC) bone metastasis by targeting melanoma differentiation associated gene-9 (mda-9/Syntenin). This drug also enhances the effectiveness of standard chemotherapy, improving survival in bone metastasis models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Bone metastasis is a significant challenge in advanced prostate cancer (PC), driven by interactions between tumor cells and bone marrow-derived mesenchymal stromal cells (BM-MSCs).
  • Melanoma differentiation associated gene-9 (mda-9/Syntenin) is a key pro-metastatic gene coordinating these tumor-stromal interactions within the bone niche.

Purpose of the Study:

  • To develop small molecule inhibitors targeting protein-protein interactions of MDA-9/Syntenin to combat PC bone metastasis.
  • To evaluate the translational potential and therapeutic efficacy of IVMT-Rx-4, a novel inhibitor of MDA-9/Syntenin.

Main Methods:

  • Investigated the role of MDA-9/Syntenin in PC bone metastasis and its interaction with BM-MSCs.
  • Synthesized and characterized IVMT-Rx-4, an intermediate of PDZ1i, assessing its bioactivity, solubility, and efflux properties.
  • Evaluated the anti-metastatic and anti-invasive effects of IVMT-Rx-4 in vitro and in vivo.
  • Assessed the combination therapy of IVMT-Rx-4 with docetaxel in experimental bone metastasis models.

Main Results:

  • IVMT-Rx-4 demonstrated potent anti-invasive and anti-metastatic effects by inhibiting MDA-9/Syntenin-dependent PDGF-AA signaling in BM-MSCs.
  • IVMT-Rx-4 exhibits improved druggable properties compared to PDZ1i, including higher solubility.
  • Combination therapy with IVMT-Rx-4 and docetaxel significantly enhanced survival in experimental bone metastasis models.

Conclusions:

  • IVMT-Rx-4 represents a promising therapeutic strategy for inhibiting prostate cancer bone metastasis.
  • IVMT-Rx-4 not only suppresses metastasis but also potentiates the efficacy of standard chemotherapy, offering a dual benefit.
  • This study provides a framework for developing translational strategies to manage complications associated with advanced prostate cancer.
Keywords:
BM-MSCCXCL5 and NF-κBMDA-9/SynteninPDGF-AA

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

840
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K